Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 104
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
8/17/2004
 
First Published:
4/23/2003
1.
Phase II/III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With Versus Without Etoposide in Older Patients With Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
70 and over
Other
EORTC-20991
NCT00060385
Last Modified:
3/8/2005
2.
Phase III Randomized Study of Standard Chemotherapy vs High-Dose Chemotherapy with Hematopoietic Rescue Using Purged vs Unpurged AuBM or PBSC in Adults with Poor-Risk Relapsed Follicular non-Hodgkin's Lymphoma (Summary Last Modified 03/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
15 to 65
MRC-ECUP
EU-93009
Last Modified:
5/4/2007
3.
Phase III Randomized Study of Sequential Treatment with 3 Noncross-Resistant Chemotherapy Combinations or Standard Chemotherapy for Poor-Prognosis Intermediate Grade and Immunoblastic non-Hodgkin's Lymphoma: IDA/CDDP/ARA-C/MePRDL, IDA/VCR/BLEO/CTX/MePRDL, and IFF/DHAD/VP-16 vs Standard CHOP (Summary Last Modified 09/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
over 15
NCI
MDA-DM-94017
NCI-T94-0040D, NCT00002565, T94-0040
Last Modified:
9/29/2008
 
First Published:
6/1/1996
4.
Phase III Randomized International Study of Reduction in Intensification of the LMB 89 Regimen for non-Hodgkin's Lymphoma: Reduced Doses of CTX for Intermediate-Risk Patients and Less Maintenance Therapy for Intermediate-Risk and High-Risk Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
over 6 months to under 21
NCI
COG-C5961
CCG-5961, SFOP-LMB-96, CCLG-NHL-9600, EU-96048, NCT00002757
Last Modified:
8/10/2006
5.
Phase III Randomized Study of Induction With the ALL-2 Regimen (Cytarabine and High-Dose Mitoxantrone Based) Versus the L-20 Regimen (Vincristine and Prednisone Based) in Adults With Acute Lymphoblastic Malignancy: The ALL-4 Protocol
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Other
MSKCC-96015A1
NCI-V96-0881, NCT00002766
Last Modified:
3/10/2004
6.
Phase III Randomized Study of High-Dose Sequential Chemotherapy Followed by Peripheral Blood Stem Cell Transplantation vs Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) for Poor-Risk, Intermediate- and High-Grade Non-Hodgkin's Lymphoma (Summary Last Modified 02/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 to 65
NCI
E-2493
E2493
Last Modified:
8/2/2007
 
First Published:
1/1/1998
7.
Phase III Randomized Study of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) With or Without Rituximab in Older Patients With Diffuse Mixed, Diffuse Large, or Immunoblastic Large Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
60 and over
NCI
ECOG-E4494
E4494, CLB-9793, SWOG-E4494, NCT00003150
Last Modified:
11/28/2006
 
First Published:
4/1/1998
8.
Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Sequential High-Dose Chemotherapy With Autologous Peripheral Blood Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 60
Other
SWS-SAKK-38/97
EU-97037, NCT00003215
Last Modified:
5/21/2007
 
First Published:
12/1/1998
9.
Phase III Randomized Study of High Dose Chemotherapy and Autologous Bone Marrow Transplantation as Initial Therapy for Poor Risk Intermediate and High Grade Adult Non-Hodgkin's Lymphoma (Summary Last Modified 05/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
16 to 65
BNLI-LY02
EU-98039, NCT00003578
Last Modified:
5/25/2007
 
First Published:
12/1/1998
10.
Phase III Randomized Study of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) With or Without Rituximab in Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
Over 18
NCI
AMC-010
CPMC-IRB-9691, CWRU-AMC-1400, UCLA-9810029, NCT00003595
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute